Side-by-side · Research reference
SS-31vsSurvodutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED9/43 cited
BPhase 3HUMAN-REVIEWED25/54 cited
SS-31
Cardiolipin-binding · Mitochondrial protective
SQ · Abdomen · Once daily
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
01Mechanism of Action
Parameter
SS-31
Survodutide
Primary target
Cardiolipin in inner mitochondrial membraneSzeto 2014
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pathway
Cardiolipin binding → cristae stabilisation → ETC integrity → reduced ROS + preserved ATP synthesisSzeto 2014Szilagyi 2009
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Downstream effect
Mitochondrial bioenergetic preservation; cardio-, neuro-, and reno-protective effects in animal + clinical studiesSzeto 2014
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Feedback intact?
—
—
Origin
Synthetic tetrapeptide D-Arg-Dmt-Lys-Phe-NH₂; cell-permeable, mitochondrial-selectiveSzeto 2014
—
Antibody development
—
—
02Dosage Protocols
Parameter
SS-31
Survodutide
Standard dose
40 mg / day SQ (clinical trials)Szeto 2014
Anecdotal community range 5-10 mg/day. Phase 3 trials use 40 mg.
Not yet disclosed (Phase 3 ongoing)
SYNCHRONIZE Phase 3 program underway.Rubino 2026
Frequency
Once daily
Once weekly
Lower / starter dose
5 mg / day (anecdotal)
—
Evidence basis
Multiple Phase 3 trials (Barth, AMD, ischemia-reperfusion)Szeto 2014Szilagyi 2009
Phase 2 RCT (obesity) · Phase 3 ongoing
Duration
Indefinite for mitochondrial disease; cycled for healthspan use
—
Reconstitution
Bacteriostatic water
—
Timing
Morning fasted preferred; pre-workout for exercise-induced mitochondrial stress
—
Half-life
~3 h plasma; tissue uptake longer
—
03Metabolic / Fat Loss Evidence
Parameter
SS-31
Survodutide
Primary fat target
—
Total body weight, visceral adipose tissue
Weight loss mechanism
—
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
Phase 2 efficacy
—
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
Metabolic markers
—
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
Network meta-analysis
—
Favorable efficacy profile vs other glucagon receptor agonists
Comparative efficacy
—
Network meta-analysis shows competitive efficacy in GRA class
04Side Effects & Safety
Parameter
SS-31
Survodutide
Injection site reaction
Erythema, mild pruritus
—
GI symptoms
Nausea (uncommon)
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Headache
Reported in some Phase 3 trials
—
Cardiovascular
Cardio-protective in studies; no signal of harm
—
Pregnancy / OB
Avoid — insufficient data
—
Safety profile
—
Network meta-analysis: comparable safety to other GRAs
Serious adverse events
—
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
Injection site reactions
—
Expected with subcutaneous administration
Glucagon-related effects
—
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
Absolute Contraindications
SS-31
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Relative Contraindications
SS-31
- ·None established
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
05Administration Protocol
Parameter
SS-31
Survodutide
1. Reconstitution
Add bacteriostatic water per label. Light-protected handling.
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
2. Injection site
SQ — abdomen or thigh. Rotate sites.
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
3. Timing
Morning fasted; pre-workout for exercise-augmented mitochondrial stress.
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
4. Storage
Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
5. Needle
29–31G, 4–8 mm insulin syringe.
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.
06Stack Synergy
SS-31
+ MOTS-c
ModerateSS-31 and MOTS-c address mitochondrial decline through complementary axes. SS-31 protects existing mitochondrial structure (cardiolipin binding, cristae stabilisation). MOTS-c upregulates AMPK/PGC-1α, triggering biogenesis of new mitochondria. Together they pair preservation with renewal — anecdotally favoured in healthspan and post-cardio-event recovery protocols.
- SS-31
- 5–10 mg SQ · daily morning
- MOTS-c
- 5 mg SQ · 2× per week pre-workout
- Primary benefit
- Mitochondrial preservation + biogenesis
Survodutide
— no documented stacks